Read about Enteris BioPharma oral drug delivery news and innovation via press releases, press coverage, & upcoming events.
- Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration October 12, 2022Peptides as drugs offer a compelling and unique approach to the treatment of various medical conditions. Peptides occupy a therapeutic niche between small molecules and large biologics.
- Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products August 8, 2022Highly potent active pharmaceutical ingredients (HPAPI) are one of the most rapidly growing segments of the drug development industry and make up a sizeable portion of the pharmaceutical product pipeline.
- HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity April 7, 2022What techniques should manufacturers employ when working with low-dose drug products?
- HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Power, Precision and Productivity March 24, 2022How to Ensure Your CDMO Partner Has the Experience and Expertise to Get Your HPAPI Product Across the Finish Line
- The 505(b)(2) Pathway – Pharma’s “Goldilocks” Opportunity November 12, 2021Breaking down the barriers to oral delivery of peptides and small molecules is no easy task, but it holds the key to enhancing myriad drug products and treatment paradigms.
- Strategies for Entering Phase 1 Clinical Development with Limited API June 1, 2021Discovery and development of new medicines to extend or improve the life of patients is a challenging and expensive endeavor. The cost of developing a new drug is estimated to be between $800 million and $2 billion and often requires 10 or more years of development with the FDA only approving, on average, 30 new ...
- DRUG DEVELOPMENT EXECUTIVE – Enteris BioPharma: How to Build a Preferred CDMO Partner June 1, 2021Since its founding in 2013, Enteris BioPharma, a clinical-stage biopharmaceutical company based in Boonton, NJ, has grown into an important player in the drug development and delivery market by utilizing its proprietary drug delivery technologies, Peptelligence® and ProPermaTM, to develop and produce oral formulations of BCS class III and IV compounds, including peptides, peptidomimetics, and ...
- SMALL MOLECULE THERAPEUTICS: Solubility with Permeability to Achieve Better Bioavailability December 20, 2020Proteins and peptides are the building blocks of life and are a very promising basis for targeting a range of diseases. Throughout the past 30 years, and especially the past 10 years, there has been a rapid growth in the development of therapeutic proteins, with a significant increase in the number of protein-based drugs on ...
- EXECUTIVE INTERVIEW – Enteris BioPharma: Pioneers in Oral Formulation Development October 2, 2020Breaking down the barriers to oral delivery of peptides and small molecules is no easy task, but it holds the key to enhancing myriad drug products and treatment paradigms.
- PEPTIDE THERAPEUTICS – Oral Peptide Therapeutics – Opportunities Abound as Barriers Fall September 2, 2020Proteins and peptides are the building blocks of life and are a very promising basis for targeting a range of diseases. Throughout the past 30 years, and especially the past 10 years, there has been a rapid growth in the development of therapeutic proteins, with a significant increase in the number of protein-based drugs on ...
